https://www.selleckchem.com/pr....oducts/20-hydroxyecd
27%, p0.001), a lower frequency of thromboembolic complications (3% vs. 5%, p0.001), and lower rates of extended hospital stays (eLOS) (20% vs. 24%, p0.001). Multivariable logistic regression analysis adjusting for demographic and baseline clinical characteristics demonstrated independent associations of IVT bridging therapy with intracranial hemorrhage (aOR 1.28, 95% CI 1.15, 1.43; p0.001), thromboembolic complications (aOR 0.66, 95% CI 0.53, 0.83; p0.001), routine discharge (aOR 1.27, 95% CI 1.15, 1.40;
Like
Comment
Share
